{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T18:32:18Z","timestamp":1790015538307,"version":"4.0.1"},"reference-count":33,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2016,7,1]],"date-time":"2016-07-01T00:00:00Z","timestamp":1467331200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2016,7,1]],"date-time":"2016-07-01T00:00:00Z","timestamp":1467331200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"name":"Anergis SA"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jacionline.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Allergy and Clinical Immunology"],"published-print":{"date-parts":[[2016,7]]},"DOI":"10.1016\/j.jaci.2016.02.044","type":"journal-article","created":{"date-parts":[[2016,5,6]],"date-time":"2016-05-06T16:40:50Z","timestamp":1462552850000},"page":"162-168","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":67,"title":["Efficacy of 2\u00a0months of allergen-specific immunotherapy with Bet v 1\u2013derived contiguous overlapping peptides in patients with allergic rhinoconjunctivitis: Results of a phase IIb study"],"prefix":"10.1016","volume":"138","author":[{"given":"Fran\u00e7ois","family":"Spertini","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gilles","family":"DellaCorte","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander","family":"Kettner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fr\u00e9d\u00e9ric","family":"de Blay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lars","family":"Jacobsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marek","family":"Jutel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Margitta","family":"Worm","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vincent","family":"Charlon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christophe","family":"Reymond","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jaci.2016.02.044_bib1","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1046\/j.1398-9995.2003.00387.x","article-title":"Clinical efficacy of sublingual and subcutaneous birch pollen allergen-specific immunotherapy: a randomized, placebo-controlled, double-blind, double-dummy study","volume":"59","author":"Khinchi","year":"2004","journal-title":"Allergy"},{"key":"10.1016\/j.jaci.2016.02.044_bib2","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1067\/mai.2001.119743","article-title":"A double-blinded, comparative study of the effects of short preseason specific immunotherapy and topical steroids in patients with allergic rhinoconjunctivitis and asthma","volume":"108","author":"Rak","year":"2001","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2016.02.044_bib3","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1034\/j.1398-9995.2000.00367.x","article-title":"Allergen-specific immunotherapy in birch- and grass-pollen-allergic rhinitis. I. Efficacy estimated by a model reducing the bias of annual differences in pollen counts","volume":"55","author":"Winther","year":"2000","journal-title":"Allergy"},{"key":"10.1016\/j.jaci.2016.02.044_bib4","doi-asserted-by":"crossref","first-page":"1326","DOI":"10.1046\/j.1365-2222.1999.00651.x","article-title":"Short-term preseasonal birch pollen allergoid immunotherapy influences symptoms, specific nasal provocation and cytokine levels in nasal secretions, but not peripheral T-cell responses, in patients with allergic rhinitis","volume":"29","author":"Klimek","year":"1999","journal-title":"Clin Exp Allergy"},{"key":"10.1016\/j.jaci.2016.02.044_bib5","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1046\/j.1365-2222.2003.01564.x","article-title":"Hymenoptera ultra-rush venom immunotherapy (210 min): a safety study and risk factors","volume":"33","author":"Birnbaum","year":"2003","journal-title":"Clin Exp Allergy"},{"key":"10.1016\/j.jaci.2016.02.044_bib6","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1034\/j.1398-9995.2000.00368.x","article-title":"Allergen-specific immunotherapy in birch- and grass-pollen-allergic rhinitis. II. Side-effects","volume":"55","author":"Winther","year":"2000","journal-title":"Allergy"},{"key":"10.1016\/j.jaci.2016.02.044_bib7","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1186\/2045-7022-3-17","article-title":"Novel birch pollen specific immunotherapy formulation based on contiguous overlapping peptides","volume":"3","author":"Pellaton","year":"2013","journal-title":"Clin Transl Allergy"},{"key":"10.1016\/j.jaci.2016.02.044_bib8","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/j.jaci.2014.04.001","article-title":"Safety and immunogenicity of immunotherapy with Bet v 1-derived contiguous overlapping peptides","volume":"134","author":"Spertini","year":"2014","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2016.02.044_bib9","unstructured":"Pollen info. Available at: www.polleninfo.com. 2013. Accessed May 27, 2016."},{"key":"10.1016\/j.jaci.2016.02.044_bib10","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1046\/j.1365-2222.2000.00668.x","article-title":"Development and validation of the mini Rhinoconjunctivitis Quality of Life Questionnaire","volume":"30","author":"Juniper","year":"2000","journal-title":"Clin Exp Allergy"},{"key":"10.1016\/j.jaci.2016.02.044_bib11","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.jaci.2010.11.035","article-title":"Efficacy and safety of timothy grass allergy immunotherapy tablet treatment in North American adults","volume":"127","author":"Nelson","year":"2011","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2016.02.044_bib12","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1111\/j.1398-9995.2006.01312.x","article-title":"Recommendations for standardization of cliical trials with Allergen Specific Immunotherapy for respiratory allergy. A\u00a0statement of a World Allergy Organization (WAO) taskforce","volume":"62","author":"Canonica","year":"2007","journal-title":"Allergy"},{"key":"10.1016\/j.jaci.2016.02.044_bib13","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1016\/j.jaci.2009.10.060","article-title":"Speaking the same language: the World Allergy Organization Subcutaneous Immunotherapy Systemic Reaction Grading System","volume":"125","author":"Cox","year":"2010","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2016.02.044_bib14","doi-asserted-by":"crossref","first-page":"1308","DOI":"10.1016\/S0140-6736(05)61026-4","article-title":"Forest plots and the interpretation of subgroups","volume":"365","author":"Cuzick","year":"2005","journal-title":"Lancet"},{"key":"10.1016\/j.jaci.2016.02.044_bib15","series-title":"Statistical analysis with missing data","author":"Little","year":"1987"},{"key":"10.1016\/j.jaci.2016.02.044_bib16","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.1016\/0091-6749(90)90045-6","article-title":"Effect of seasonal exposure to pollen on specific bronchial sensitivity in allergic patients","volume":"85","author":"Crimi","year":"1990","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2016.02.044_bib17","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.jaci.2009.10.035","article-title":"Long-term clinical efficacy in grass pollen-induced rhinoconjunctivitis after treatment with SQ-standardized grass allergy immunotherapy tablet","volume":"125","author":"Durham","year":"2010","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2016.02.044_bib18","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1016\/j.anai.2013.11.018","article-title":"Efficacy\u00a0and safety of grass sublingual immunotherapy tablet, MK-7243: a\u00a0large\u00a0randomized controlled trial","volume":"112","author":"Maloney","year":"2014","journal-title":"Ann Allergy Asthma Immunol"},{"key":"10.1016\/j.jaci.2016.02.044_bib19","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1111\/all.12622","article-title":"Development\u00a0and evaluation of a sublingual tablet based on recombinant Bet v 1 in birch pollen-allergic patients","volume":"70","author":"Nony","year":"2015","journal-title":"Allergy"},{"key":"10.1016\/j.jaci.2016.02.044_bib20","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/j.anai.2014.11.015","article-title":"SQ house dust mite sublingually administered immunotherapy tablet (ALK) improves allergic rhinitis in patients with house dust mite allergic asthma and rhinitis symptoms","volume":"114","author":"Mosbech","year":"2015","journal-title":"Ann Allergy Asthma Immunol"},{"key":"10.1016\/j.jaci.2016.02.044_bib21","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.jaci.2010.11.029","article-title":"Development and preliminary clinical evaluation of a peptide immunotherapy vaccine for cat allergy","volume":"127","author":"Worm","year":"2011","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2016.02.044_bib22","doi-asserted-by":"crossref","first-page":"8017","DOI":"10.1128\/IAI.73.12.8017-8026.2005","article-title":"Phase I malaria vaccine trial with a long synthetic peptide derived from the merozoite surface protein 3 antigen","volume":"73","author":"Audran","year":"2005","journal-title":"Infect Immun"},{"key":"10.1016\/j.jaci.2016.02.044_bib23","doi-asserted-by":"crossref","first-page":"e7304","DOI":"10.1371\/journal.pone.0007304","article-title":"The synthetic Plasmodium falciparum circumsporozoite peptide PfCS102 as a malaria vaccine candidate: a randomized controlled phase I trial","volume":"4","author":"Audran","year":"2009","journal-title":"PLoS One"},{"key":"10.1016\/j.jaci.2016.02.044_bib24","doi-asserted-by":"crossref","first-page":"854","DOI":"10.1067\/mai.2003.1337","article-title":"Allergen-specific T-cell tolerance induction with allergen-derived long synthetic peptides: results of a phase I trial","volume":"111","author":"Fellrath","year":"2003","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2016.02.044_bib25","doi-asserted-by":"crossref","first-page":"1638","DOI":"10.1002\/1521-4141(200006)30:6<1638::AID-IMMU1638>3.0.CO;2-R","article-title":"Allergen-derived long peptide immunotherapy down-regulates specific IgE response and protects from anaphylaxis","volume":"30","author":"von Garnier","year":"2000","journal-title":"Eur J Immunol"},{"key":"10.1016\/j.jaci.2016.02.044_bib26","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1006\/clim.1999.4795","article-title":"The safety and efficacy of ALLERVAX CAT in cat allergic patients","volume":"93","author":"Maguire","year":"1999","journal-title":"Clin Immunol"},{"key":"10.1016\/j.jaci.2016.02.044_bib27","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/S0140-6736(02)09332-7","article-title":"Effect of T-cell peptides derived from Fel d 1 on allergic reactions and cytokine production in patients sensitive to cats: a randomised controlled trial","volume":"360","author":"Oldfield","year":"2002","journal-title":"Lancet"},{"key":"10.1016\/j.jaci.2016.02.044_bib28","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1111\/j.1365-2222.2005.02143.x","article-title":"Fel d 1-derived T cell peptide therapy induces recruitment of CD4+ CD25+; CD4+ interferon-gamma+ T helper type 1 cells to sites of allergen-induced late-phase skin reactions in cat-allergic subjects","volume":"35","author":"Alexander","year":"2005","journal-title":"Clin Exp Allergy"},{"key":"10.1016\/j.jaci.2016.02.044_bib29","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1067\/mai.2001.117460","volume":"108","author":"Haselden","year":"2001","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2016.02.044_bib30","doi-asserted-by":"crossref","first-page":"1514","DOI":"10.1111\/j.1365-2222.2008.03042.x","article-title":"Clinical effects of immunotherapy with genetically modified recombinant birch pollen Bet v 1 derivatives","volume":"38","author":"Purohit","year":"2008","journal-title":"Clin Exp Allergy"},{"key":"10.1016\/j.jaci.2016.02.044_bib31","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1111\/j.1365-2222.2009.03207.x","article-title":"Immunoglobulin G4: an odd antibody","volume":"39","author":"Aalberse","year":"2009","journal-title":"Clin Exp Allergy"},{"key":"10.1016\/j.jaci.2016.02.044_bib32","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.jaci.2012.07.028","article-title":"Fel\u00a0d\u00a01-derived peptide antigen desensitization shows a persistent treatment effect 1 year after the start of dosing: a randomized, placebo-controlled study","volume":"131","author":"Patel","year":"2013","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2016.02.044_bib33","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1016\/j.jaci.2008.09.017","article-title":"Efficacy of recombinant birch pollen vaccine for the treatment of birch-allergic rhinoconjunctivitis","volume":"122","author":"Pauli","year":"2008","journal-title":"J Allergy Clin Immunol"}],"container-title":["Journal of Allergy and Clinical Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S009167491630255X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S009167491630255X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,25]],"date-time":"2025-09-25T08:56:39Z","timestamp":1758790599000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S009167491630255X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,7]]},"references-count":33,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2016,7]]}},"alternative-id":["S009167491630255X"],"URL":"https:\/\/doi.org\/10.1016\/j.jaci.2016.02.044","relation":{},"ISSN":["0091-6749"],"issn-type":[{"value":"0091-6749","type":"print"}],"subject":[],"published":{"date-parts":[[2016,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Efficacy of 2\u00a0months of allergen-specific immunotherapy with Bet v 1\u2013derived contiguous overlapping peptides in patients with allergic rhinoconjunctivitis: Results of a phase IIb study","name":"articletitle","label":"Article Title"},{"value":"Journal of Allergy and Clinical Immunology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jaci.2016.02.044","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 American Academy of Allergy, Asthma & Immunology","name":"copyright","label":"Copyright"}]}}